Artiva Biotherapeutics Inc.
Artiva Biotherapeutics is focused on developing and commercializing off-the-shelf cell therapies for patients with hematologic malignancies or solid tumors. Our pipeline of universal and targeted product candidates exploits the innate biology and safety features of Natural Killer (NK) cells, while seeking to enhance their efficacy through antibody combination therapy and genetic engineering. Our product pipeline includes unmodified cord blood-derived NK cells, genetically modified and gene edited NK-CARs, and iPSC-derived NK cells, each building on the discovery, preclinical development, and large scale manufacturing success of our corporate partner. The core technology for our initial product candidates is currently being evaluated by our partner in Phase 2 clinical studies in Korea, and we expect to initiate U.S. clinical trials for the first Artiva candidate, AB-101, in 2020.
